IOncology

The 2026 Pujiang Prostate Cancer Summit was successfully held in Shanghai on June 26–27. Hosted by the Shanghai Anti-Cancer Association and organized by Fudan University Shanghai Cancer Center, the meeting brought together leading experts through keynote lectures, multidisciplinary (MDT) discussions, and live surgical demonstrations to highlight the latest advances in prostate cancer management. Among the meeting's major themes, personalized and precision treatment strategies attracted particular attention.

The 2026 Pujiang Prostate Cancer Summit was held in Shanghai on June 26–27 under the theme "Standardization, Precision, Chinese Innovation, and Global Collaboration." The meeting brought together leading experts in genitourinary oncology to showcase the latest advances in standardized prostate cancer management and innovative treatment strategies.

In this edition of Clear Horizons, Comprehensive Urologic Care, Professor Xin Yao from Tianjin Medical University Cancer Institute and Hospital discusses the mechanistic and clinical differences between LHRH agonists and antagonists, as well as practical strategies for managing ADT-related adverse events to maximize both treatment efficacy and patient quality of life.

Cholangiocarcinoma is characterized by its high malignancy, with the majority of patients presenting with unresectable disease at initial diagnosis. In recent years, conversion therapy—which utilizes systemic treatment to downsize tumors—has emerged as a pivotal, offering select patients a pathway to curative-intent resection. However, striking the right balance between therapeutic efficacy and overtreatment remains a significant clinical challenge. At APPLE 2026, Prof. Stephen L. Chan, from the Chinese University of Hong Kong (CUHK) Faculty of Medicine, offered an in-depth analysis of these issues during an exclusive interview with our journal. Prof. Chen advocates for earlier genomic testing for alterations such as FGFR2 and IDH1, and proposes a multidimensional assessment framework combining radiology with circulating biomarkers like ctDNA and MRD to precisely identify the optimal surgical window. Furthermore, he recommends a stratified postoperative strategy guided by pathological response (MPR/pCR) to maximize recurrence-free survival.

From July 3–5, 2026, the 16th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2026) will be held in Shanghai. Initiated by the Asia-Pacific Primary Liver Cancer Expert Association (APPLE), supported by the Shanghai Xinxin Medical Technology Development Foundation, and hosted by Zhongshan Hospital, Fudan University, the meeting will focus on the theme "Frontiers in the Diagnosis and Treatment of Primary Liver Cancer in the Era of Artificial Intelligence." Bringing together leading liver cancer experts from the Asia-Pacific region, Europe, and North America, APPLE 2026 will explore emerging strategies for liver cancer prevention and treatment. Following previous editions in 2012 and 2022, this marks the third time APPLE has been hosted in Shanghai, highlighting China's remarkable progress in healthcare, scientific research, and innovation over the past decade. Ahead of the meeting, Oncology Frontier spoke with Congress President Academician Jia Fan of Zhongshan Hospital, Fudan University, who reflected on APPLE's evolution, discussed the changing role of Chinese liver cancer specialists on the global stage, and shared his vision for how artificial intelligence (AI) will transform liver cancer care. Stay tuned for this landmark event.

On-site at the 2026 ASCO Annual Meeting, the targeted therapy landscape for ALK-positive non-small cell lung cancer (NSCLC) is witnessing intense competition, with multiple frontline updates from cutting-edge studies reshaping the global dynamics. As a pioneering Chinese homegrown innovative drug making its way onto the world stage, how can ensartinib—Betta Pharmaceuticals' proprietary ALK inhibitor—demonstrate its core value amidst formidable international rivals? MediaMedic had the privilege of an exclusive on-site interview with Professor Li Mao, President of R&D and Chief Medical Officer at Betta Pharmaceuticals, a seasoned leader deeply engaged in precision oncology, to deconstruct ensartinib's distinctive pathway to differentiation and global breakthrough. ADD HASHTAGS

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, 2026, showcased several practice-changing advances in oncology. Among the highlights, Prof. Kohei Shitara from the National Cancer Center Hospital East, Japan, presented additional health-related quality of life (HRQoL) data from the landmark DESTINY-Gastric04 trial, further demonstrating the benefits of trastuzumab deruxtecan (T-DXd) in preserving patients' quality of life.